Twist Bioscience CFO’s “Sell‑to‑Cover” Move Sparks Insider‑Market Speculation as Stock Soars 29% in March 2026
Twist Bioscience insider sell‑to‑cover: CFO Adam’s 2,738‑share sale post‑price surge shows routine tax compliance, not a red flag, and underscores the company’s synthetic‑DNA growth potential.
3 minutes to read